MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
07 2019
Historique:
received: 15 10 2018
accepted: 27 02 2019
revised: 17 02 2019
pubmed: 3 4 2019
medline: 28 4 2020
entrez: 3 4 2019
Statut: ppublish

Résumé

Leukoplakia is a potential precursor of oral as well as laryngeal squamous cell carcinoma. Risk assessment of malignant transformation based on the grade of dysplasia of leukoplakia often does not lead to reliable results. However, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, and leukoplakia express single or multiple members of the melanoma-associated antigens A (MAGE-A) family, while MAGE-A are absent in healthy mucosal tissue. The present study aimed at determining if there is an association between the expression of MAGE-A in leukoplakia and malignant transformation to oral or laryngeal squamous cell carcinoma. Paraffin-embedded tissues of 205 oral and laryngeal leukoplakia, 90 corresponding tumors, and 40 healthy oral mucosal samples were included in the study. The grade of dysplasia of the leukoplakia samples was determined histopathologically. The leukoplakia samples were divided into lesions that transformed to oral and laryngeal squamous cell carcinoma (n = 91) and lesions that did not (n = 114) during a 5 years follow-up. The expression of MAGE-A3/6 and MAGE-A4 was analyzed by real-time RT-PCR. The expression of MAGE-A 1-4, 6, and 12 was determined by immunohistochemistry. A total of 59.3% of the transforming leukoplakia expressed at least one of the examined antigens as opposed to an expression rate of 3.5% of all non-transforming leukoplakia. There was no MAGE-A expression in healthy oral mucosa. The risk of malignant transformation was statistically significantly associated with MAGE-A expression in immunohistochemistry (p < 0.001) and real-time RT-PCR (MAGE-A3/6, p = 0.001; MAGE-A4, p = 0.002) analyses. There was no significant association between MAGE-A expression and the grade of dysplasia ("low-grade", D0/D1; "high-grade", D2/D3) in immunohistochemistry (p = 0.412) and real-time RT-PCR (MAGE-A3/6, p = 0.667; MAGE-A4, p = 0.756). It seems that the analysis of the MAGE-A expression profile may support the identification of leukoplakia at risk for malignant transformation. Therefore, efforts should be made to establish this analysis as a routine procedure in addition to conventional histopathology.

Identifiants

pubmed: 30936424
doi: 10.1038/s41379-019-0253-5
pii: S0893-3952(22)01025-0
doi:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers, Tumor 0
MAGEA3 protein, human 0
MAGEA4 protein, human 0
MAGEA6 protein, human 0
Neoplasm Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1068-1081

Auteurs

Christoph A Baran (CA)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. ChristophBaran@gmx.de.

Abbas Agaimy (A)

Institute of Pathology, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Falk Wehrhan (F)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Manuel Weber (M)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Verena Hille (V)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Kathrin Brunner (K)

Institute of Pathology, Hospital Weiden, Weiden, Germany.

Claudia Wickenhauser (C)

Institute of Pathology, Halle (Saale) University Hospital, Martin-Luther University Halle-Wittenberg (MLU), Halle (Saale), Germany.

Udo Siebolts (U)

Institute of Pathology, Halle (Saale) University Hospital, Martin-Luther University Halle-Wittenberg (MLU), Halle (Saale), Germany.

Emeka Nkenke (E)

Department of Oral and Maxillofacial Surgery, Vienna General Hospital (AKH Wien), Medical University of Vienna, Vienna, Austria.

Marco Kesting (M)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Jutta Ries (J)

Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH